Expression of anti-Müllerian hormone in letrozole rat model of polycystic ovary syndrome. (December 2014)

• Record Type: Journal Article
• Authors: Du, Dan-Feng; Li, Xue-Lian; Fang, Fang; Du, Mei-Rong
• Is Part Of: Gynecological endocrinology. Volume 30:Number 12(2014:Dec.)
• Page Start: 885
• Page End: 889
• Publication Date: 2014-12
• Subjects: Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.3109/09513590.2014.943723
• Languages: English
• ISSNs: 0951-3590

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age with anti-müllerian hormone (AMH) two to three times higher, but the mechanism of increased AMH, excessive follicles and follicle stagnation in PCOS still needs further research.</p> <p> <italic>Methods</italic>: Female Sprague–Dawley rats were treated with a gavage of 1.0 mg/kg of letrozole carboxymethylcellulose solution once daily for 21 consecutive days. Serum steroid concentrations, ovarian morphology, ovarian expression of AMH and AMH-RII protein were determined and their relationships were studied.</p> <p> <italic>Results</italic>: According to the morphology and endocrinology, the letrozole model group was a successful PCOS model. Serum AMH and ovarian local expression of AMH and AMH-RII were both increased in letrozole model group. The elevated AMH had a positive correlation with T, growing follicle count and a negative correlation with body weight.</p> <p> <italic>Conclusions</italic>: The letrozole model group is a good animal model for the study of AMH in PCOS patients with obesity or insulin resistance. The increased serum AMH level in PCOS is the consequence of the androgen-induced excess of small antral follicles. These results lead to the hypothesis that reducing AMH may become a therapeutic target of PCOS, which is worth further research.</p> </abstract>